BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 18196747)

  • 1. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.
    Hosoya K; Kisseberth WC; Lord LK; Alvarez FJ; Lara-Garcia A; Kosarek CE; London CA; Couto CG
    J Vet Intern Med; 2007; 21(6):1355-63. PubMed ID: 18196747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
    Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
    J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
    Garrett LD; Thamm DH; Chun R; Dudley R; Vail DM
    J Vet Intern Med; 2002; 16(6):704-9. PubMed ID: 12465768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
    Wang SL; Lee JJ; Liao AT
    Vet J; 2016 Jul; 213():87-9. PubMed ID: 27240922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol.
    Tomiyasu H; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
    J Vet Med Sci; 2010 Nov; 72(11):1391-7. PubMed ID: 20543531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
    Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
    J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
    Wang SL; Lee JJ; Liao AT
    Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
    Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
    Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
    Wang SL; Lee JJ; Liao AT
    Can Vet J; 2016 Mar; 57(3):271-6. PubMed ID: 26933263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma.
    Lautscham EM; Kessler M; Ernst T; Willimzig L; Neiger R
    Vet Rec; 2017 Mar; 180(12):303. PubMed ID: 28100766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
    Zemann BI; Moore AS; Rand WM; Mason G; Ruslander DM; Frimberger AE; Wood CA; L'Heureux DA; Gliatto J; Cotter SM
    J Vet Intern Med; 1998; 12(6):465-70. PubMed ID: 9857340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma.
    Lurie DM; Gordon IK; Théon AP; Rodriguez CO; Suter SE; Kent MS
    J Vet Intern Med; 2009; 23(5):1064-70. PubMed ID: 19627472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
    Simon D; Nolte I; Eberle N; Abbrederis N; Killich M; Hirschberger J
    J Vet Intern Med; 2006; 20(4):948-54. PubMed ID: 16955821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
    Burton JH; Garrett-Mayer E; Thamm DH
    Vet Comp Oncol; 2013 Dec; 11(4):306-15. PubMed ID: 22548975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?
    Hahn KA; Richardson RC; Teclaw RF; Cline JM; Carlton WW; DeNicola DB; Bonney PL
    J Vet Intern Med; 1992; 6(1):3-10. PubMed ID: 1548624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
    Chun R; Garrett LD; Vail DM
    J Vet Intern Med; 2000; 14(2):120-4. PubMed ID: 10772481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy with cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP) in childhood acute lymphoblastic leukemia (ALL).
    Sallan SE; Camitta BM; Chan DM; Traggis D; Jaffe N
    Med Pediatr Oncol; 1977; 3(4):359-64. PubMed ID: 270608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases.
    Sorenmo K; Overley B; Krick E; Ferrara T; LaBlanc A; Shofer F
    Vet Comp Oncol; 2010 Sep; 8(3):196-208. PubMed ID: 20691027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of combination l-asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi-centric T-cell or hypercalcaemic lymphoma.
    Angelo G; Cronin K; Keys D
    J Small Anim Pract; 2019 Jul; 60(7):430-437. PubMed ID: 30790291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs.
    Rassnick KM; Bailey DB; Malone EK; Intile JL; Kiselow MA; Flory AB; Barlow LL; Balkman CE; Barnard SM; Waite AH
    Vet Comp Oncol; 2010 Dec; 8(4):243-53. PubMed ID: 21062406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.